Skip to main content
Top
Published in: American Journal of Clinical Dermatology 1/2012

01-02-2012 | Case Letter

KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor

Authors: Dr Rubeta N. Matin, David Gonzalez, Lisa Thompson, Sally R. Lambert, Farrah Bakr, Nathalie Dhomen, Richard Marais, Jane M. McGregor, Peter Szlosarek, Rino Cerio, Catherine A. Harwood

Published in: American Journal of Clinical Dermatology | Issue 1/2012

Login to get access

Excerpt

To the Editor: Molecular events may determine clinicopathologic types of melanoma. Aberrations affecting the KIT oncogene have been demonstrated in mucosal and acral melanomas and in melanomas on chronically sun-exposed areas.[1] Improved understanding of such genotype-phenotype correlations impacts on the development of therapies. Similarly, progress has been achieved in targeted treatment with tyrosine kinase inhibitors (for example, imatinib) of gastrointestinal stromal tumors (GISTs), in which KIT mutations occur in up to 80% of cases. To date, significant responses to imatinib have also been demonstrated in melanomas harboring KIT mutations.[2,3] We report the first case of synchronous GIST and lentigo maligna melanoma (LMM) in the same patient where oncogenic KIT may play an important role and in whom molecular genotyping was undertaken to determine whether targeted chemotherapy with imatinib might be justified. …
Literature
1.
go back to reference Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24 (26): 4340–6PubMedCrossRef Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24 (26): 4340–6PubMedCrossRef
2.
go back to reference Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106 (9): 2005–11PubMedCrossRef Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106 (9): 2005–11PubMedCrossRef
3.
go back to reference Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14 (23): 7726–32PubMedCrossRef Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14 (23): 7726–32PubMedCrossRef
4.
go back to reference Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23 (12): 2735–43PubMedCrossRef Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23 (12): 2735–43PubMedCrossRef
5.
go back to reference Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14 (21): 6821–8PubMedCrossRef Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14 (21): 6821–8PubMedCrossRef
6.
go back to reference Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009; 22 (11): 1446–56PubMedCrossRef Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009; 22 (11): 1446–56PubMedCrossRef
7.
go back to reference Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121 (2): 257–64PubMedCrossRef Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121 (2): 257–64PubMedCrossRef
Metadata
Title
KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor
Authors
Dr Rubeta N. Matin
David Gonzalez
Lisa Thompson
Sally R. Lambert
Farrah Bakr
Nathalie Dhomen
Richard Marais
Jane M. McGregor
Peter Szlosarek
Rino Cerio
Catherine A. Harwood
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 1/2012
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/11593910-000000000-00000

Other articles of this Issue 1/2012

American Journal of Clinical Dermatology 1/2012 Go to the issue

Review Article

Body Piercing